IDEAYA Biosciences (IDYA) EBIAT (2019 - 2025)
IDEAYA Biosciences (IDYA) has disclosed EBIAT for 7 consecutive years, with -$83.3 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 36.1% to -$83.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$113.7 million through Dec 2025, up 58.58% year-over-year, with the annual reading at -$113.7 million for FY2025, 58.58% up from the prior year.
- EBIAT hit -$83.3 million in Q4 2025 for IDEAYA Biosciences, down from $119.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $119.2 million in Q3 2025 to a low of -$130.3 million in Q4 2024.
- Historically, EBIAT has averaged -$30.5 million across 5 years, with a median of -$25.8 million in 2022.
- Biggest five-year swings in EBIAT: plummeted 1799.07% in 2023 and later soared 330.11% in 2025.
- Year by year, EBIAT stood at -$18.2 million in 2021, then tumbled by 32.88% to -$24.2 million in 2022, then tumbled by 40.3% to -$34.0 million in 2023, then crashed by 283.78% to -$130.3 million in 2024, then soared by 36.1% to -$83.3 million in 2025.
- Business Quant data shows EBIAT for IDYA at -$83.3 million in Q4 2025, $119.2 million in Q3 2025, and -$77.5 million in Q2 2025.